{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T18:50:56Z","timestamp":1774205456399,"version":"3.50.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"KAKENHI","doi-asserted-by":"publisher","award":["22K08544"],"award-info":[{"award-number":["22K08544"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To identify predictors of relapse in patients with idiopathic inflammatory myopathies (IIMs) and investigate the biological mechanisms underlying these associations using cytokine profiling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study of 99 patients who achieved remission after initial treatment for IIMs or myositis-specific antibody-positive interstitial lung disease at Nagasaki University Hospital. Among 197 diagnosed patients, we included those who achieved clinical improvement and were followed up for \u22653\u2009months, excluding early deaths and those with insufficient follow-up. Relapse was defined as disease worsening requiring treatment intensification. Risk factors were analyzed using the Cox regression analysis. Serum cytokine profiles were compared between patients with low and high pre-treatment albumin levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-one patients (41%) relapsed. Multivariate analysis revealed that pretreatment albumin level remained the only independent predictor of overall relapse (HR, 0.60; 95% CI: 0.40\u20130.92, P\u2009=\u20090.019). For ILD relapse, both albumin (HR: 0.51, 95% CI: 0.30\u20130.88, P\u2009=\u20090.015) and female sex (HR: 0.70, 95% CI: 0.52\u20130.95, P\u2009=\u20090.022) remained independent predictors. In antibody-specific analyses, the V-neck sign strongly predicted ILD relapse in anti-ARS-positive patients (HR, 5.07; 95% CI: 1.64\u201315.75, P\u2009=\u20090.006). After false discovery rate correction, 14 cytokines remained significantly elevated in patients with low albumin levels, including IL-6 (7.5-fold, q\u2009&amp;lt;\u20090.001), IP-10 (5.3-fold, q\u2009&amp;lt;\u20090.001) and MCP-1 (2.5-fold, q\u2009&amp;lt;\u20090.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pretreatment albumin levels independently predict relapse in IIMs, and cytokine profiling demonstrates that low albumin levels reflect active systemic inflammation. These findings support the use of albumin as a practical biomarker for risk stratification in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rap\/rkag021","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T12:34:00Z","timestamp":1769949240000},"source":"Crossref","is-referenced-by-count":0,"title":["Pre-treatment serum albumin predicts relapse in idiopathic inflammatory myopathies: a retrospective cohort study with cytokine profiling"],"prefix":"10.1093","volume":"10","author":[{"given":"Haruna","family":"Matsuo","sequence":"first","affiliation":[{"name":"Division of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0036-2039","authenticated-orcid":false,"given":"Toshimasa","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Division of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2077-4428","authenticated-orcid":false,"given":"Tomohiro","family":"Koga","sequence":"additional","affiliation":[{"name":"Division of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7577-476X","authenticated-orcid":false,"given":"Noriho","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Division of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"2026032213520229600_rkag021-B1","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory muscle diseases","volume":"372","author":"Dalakas","year":"2015","journal-title":"N Engl J Med"},{"key":"2026032213520229600_rkag021-B2","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026032213520229600_rkag021-B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026032213520229600_rkag021-B4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J Intern Med"},{"key":"2026032213520229600_rkag021-B5","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1093\/rheumatology\/keaf116","article-title":"Treatment guidelines for idiopathic inflammatory myopathies in adults: a comparative review","volume":"64","author":"Paik","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026032213520229600_rkag021-B6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/rheumatology\/41.1.22","article-title":"Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality","volume":"41","author":"Sultan","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"2026032213520229600_rkag021-B7","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1007\/s10067-024-07120-1","article-title":"Relapse risk factors and clinical characteristics of idiopathic inflammatory myopathies in 105 patients","volume":"43","author":"Choi","year":"2024","journal-title":"Clin Rheumatol"},{"key":"2026032213520229600_rkag021-B8","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2026032213520229600_rkag021-B9","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","article-title":"The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM","volume":"51","author":"Koga","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2026032213520229600_rkag021-B10","doi-asserted-by":"crossref","first-page":"733599","DOI":"10.3389\/fmed.2021.733599","article-title":"A clinical risk model to predict rapidly progressive interstitial lung disease incidence in dermatomyositis","volume":"8","author":"Li","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026032213520229600_rkag021-B11","doi-asserted-by":"crossref","first-page":"9141420","DOI":"10.1155\/2019\/9141420","article-title":"Biomarkers in adult dermatomyositis: tools to help the diagnosis and predict the clinical outcome","volume":"2019","author":"Cassius","year":"2019","journal-title":"J Immunol Res"},{"key":"2026032213520229600_rkag021-B12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2026032213520229600_rkag021-B13","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mjd.2002.120621","article-title":"Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?","volume":"46","author":"Sontheimer","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"2026032213520229600_rkag021-B14","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.3390\/jcm12186017","article-title":"Serum albumin levels: a biomarker to be repurposed in different disease settings in clinical practice","volume":"12","author":"Gremese","year":"2023","journal-title":"J Clin Med"},{"key":"2026032213520229600_rkag021-B15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/art.41566","article-title":"Risk prediction modeling based on a combination of initial serum biomarker levels in polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"73","author":"Gono","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026032213520229600_rkag021-B16","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2026032213520229600_rkag021-B17","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","article-title":"Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases","volume":"95","author":"Allenbach","year":"2020","journal-title":"Neurology"},{"key":"2026032213520229600_rkag021-B18","doi-asserted-by":"crossref","first-page":"103455","DOI":"10.1016\/j.autrev.2023.103455","article-title":"Idiopathic inflammatory myopathies \u2013 the burden of disease: cohort analysis focusing on damage and comorbidities","volume":"22","author":"Campar","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2026032213520229600_rkag021-B19","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10067-018-4353-2","article-title":"Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease","volume":"38","author":"Cobo-Ibanez","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2026032213520229600_rkag021-B20","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.3389\/fimmu.2018.02279","article-title":"Sex hormones in acquired immunity and autoimmune disease","volume":"9","author":"Moulton","year":"2018","journal-title":"Front Immunol"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkag021\/66792477\/rkag021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/10\/2\/rkag021\/66792477\/rkag021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/10\/2\/rkag021\/66792477\/rkag021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T17:52:11Z","timestamp":1774201931000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkag021\/8466024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,18]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkag021","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"rkag021"}}